{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:06:05Z","timestamp":1782497165997,"version":"3.54.5"},"reference-count":144,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Osteolytic bone disease is present in about 80% of patients with multiple myeloma at the time of diagnosis. Managing bone disease in patients with multiple myeloma is a challenge and requires a multi-faceted treatment approach with medication, surgery, and radiation. The established treatments with intravenous or subcutaneous antiresorptives can cause debilitating adverse events for patients, mainly osteonecrosis of the jaw, which, traditionally, has been difficult to manage. Now, oral surgery is recommended and proven successful in 60\u201385% of patients. Patients with spinal involvement may benefit from surgery in the form of vertebroplasty and kyphoplasty for pain relief, improved mobility, and reestablished sagittal balance, as well as the restoration of vertebral height. These procedures are considered safe, but the full therapeutic impact needs to be investigated further. Ixazomib, the first oral proteasome inhibitor, increases osteoblast differentiation, and recently published preliminary results in patients treated with Ixazomib maintenance have promisingly shown increased trabecular volume caused by prolonged bone formation activity. Other novel potential treatment strategies are discussed as well.<\/jats:p>","DOI":"10.3390\/cancers15235585","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:35:06Z","timestamp":1701056106000},"page":"5585","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease"],"prefix":"10.3390","volume":"15","author":[{"given":"Martin","family":"Johansen","sequence":"first","affiliation":[{"name":"Department of Hematology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-382X","authenticated-orcid":false,"given":"Mette B\u00f8egh","family":"Levring","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-7001","authenticated-orcid":false,"given":"Kasper","family":"Stokbro","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"},{"name":"Department of Oral and Maxillofacial Surgery, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7719-6839","authenticated-orcid":false,"given":"Marta","family":"Diaz-delCastillo","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Aarhus University, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Ahad","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Adsb\u00f8ll","family":"Wickstroem","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"},{"name":"Center for Spine Surgery and Research, Lillebaelt Hospital, 5500 Middelfart, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Tveden","family":"Gundesen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Bruun","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Guldborg","family":"Nyvold","sequence":"additional","affiliation":[{"name":"Research Unit for Hematology & Pathology, Hematology-Pathology Research Laboratory, University of Southern Denmark & Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-8218","authenticated-orcid":false,"given":"Mikkel \u00d8sterheden","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"},{"name":"Center for Spine Surgery and Research, Lillebaelt Hospital, 5500 Middelfart, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Levin","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"},{"name":"Department of Forensic Medicine, Aarhus University, 8200 Aarhus, Denmark"},{"name":"Department of Pathology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[{"name":"Department of Hematology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3509-3780","authenticated-orcid":false,"given":"Thomas","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Hematology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15459","article-title":"Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: Findings of the Medical Research Council Myeloma IX randomised study","volume":"182","author":"Royle","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s00277-020-04356-0","article-title":"Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program","volume":"100","author":"Nielsen","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/0284186X.2013.875625","article-title":"Risk of disability pension for patients diagnosed with haematological malignancies: A register-based cohort study","volume":"53","author":"Horsboel","year":"2014","journal-title":"Acta Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: A case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Capp, J.-P., and Bataille, R. (2023). The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis. Biology, 12.","DOI":"10.3390\/biology12070990"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone","volume":"174","author":"Andersen","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2009.07980.x","article-title":"Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells","volume":"148","author":"Andersen","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Casimiro, S., Vilhais, G., Gomes, I., and Costa, L. (2021). The Roadmap of RANKL\/RANK Pathway in Cancer. Cells, 10.","DOI":"10.3390\/cells10081978"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2005.05518.x","article-title":"Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma","volume":"129","author":"Depil","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00198-018-4787-z","article-title":"Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance","volume":"30","author":"Stein","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_19","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"Sanfilippo","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","first-page":"Cd003188","article-title":"Bisphosphonates in multiple myeloma: An updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma","volume":"76","author":"Anderson","year":"2016","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Anderson","year":"2017","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ijom.2022.02.009","article-title":"Osteonecrosis of the jaw among cancer patients in Denmark: Risk and prognosis","volume":"51","author":"Gadgaard","year":"2022","journal-title":"Int. J. Oral. Maxillofac. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhang, C., Shen, G., Li, H., Xin, Y., Shi, M., Zheng, Y., Wang, M., Liu, Z., Zhao, Y., and Zhao, F. (2023). Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis. Spec. Care Dent.","DOI":"10.1111\/scd.12877"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/odi.13160","article-title":"Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges","volume":"25","author":"Schiodt","year":"2019","journal-title":"Oral. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcms.2017.01.006","article-title":"Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ)","volume":"45","author":"Panya","year":"2017","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Otto, S., Aljohani, S., Fliefel, R., Ecke, S., Ristow, O., Burian, E., Troeltzsch, M., Pautke, C., and Ehrenfeld, M. (2021). Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ). Medicina, 57.","DOI":"10.3390\/medicina57050463"},{"key":"ref_37","first-page":"Cd012432","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"7","author":"Mayer","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.oraloncology.2011.11.004","article-title":"The saxon bisphosphonate register\u2014Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws","volume":"48","author":"Schubert","year":"2012","journal-title":"Oral. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10006-020-00909-9","article-title":"Apical surgery in cancer patients receiving high-dose antiresorptive medication-a retrospective clinical study with a mean follow-up of 13 months","volume":"25","author":"Andersen","year":"2021","journal-title":"Oral. Maxillofac. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jcms.2016.07.026","article-title":"Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid\u2014A prospective study over 6 years","volume":"44","author":"Deppe","year":"2016","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_42","first-page":"e30485","article-title":"The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis","volume":"14","author":"Aboalela","year":"2022","journal-title":"Cureus"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.oooo.2021.06.003","article-title":"Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: A randomized clinical feasibility trial of drug holiday versus drug continuation","volume":"133","author":"Ottesen","year":"2022","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jcms.2018.12.014","article-title":"Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study","volume":"47","author":"Ristow","year":"2019","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10006-022-01061-2","article-title":"Surgical treatment of 61 consecutive patients with maxillary stage 3 medication-related osteonecrosis of the jaws using a pedicled buccal fat pad","volume":"27","author":"Andersen","year":"2023","journal-title":"Oral. Maxillofac. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"115676","DOI":"10.1016\/j.bone.2020.115676","article-title":"Adjuvant therapies for MRONJ: A systematic review","volume":"141","author":"Govaerts","year":"2020","journal-title":"Bone"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial","volume":"38","author":"Sim","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00198-019-05199-w","article-title":"A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: Daily versus weekly administration","volume":"31","author":"Ohbayashi","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.oooo.2018.06.007","article-title":"Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study","volume":"126","author":"Giudice","year":"2018","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.joms.2016.12.005","article-title":"Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?","volume":"75","author":"Park","year":"2017","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijom.2016.10.008","article-title":"Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: A randomized controlled feasibility study","volume":"46","author":"Ristow","year":"2017","journal-title":"Int. J. Oral. Maxillofac. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.joms.2017.10.024","article-title":"Can Autofluorescence Guide Surgeons in the Treatment of Medication-Related Osteonecrosis of the Jaw? A Prospective Feasibility Study","volume":"76","author":"Giudice","year":"2018","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103475","DOI":"10.1016\/j.otsr.2022.103475","article-title":"Is bisphosphonate use a risk factor for atypical periprosthetic\/peri-implant fractures?\u2014A metanalysis of retrospective cohort studies and systematic review of the current evidence","volume":"109","author":"Ferreira","year":"2023","journal-title":"Orthop. Traumatol. Surg. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2017.02.007","article-title":"Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients","volume":"17","author":"Nambo","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S2152-2650(23)01577-X","article-title":"OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma","volume":"23","author":"Gundesen","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood-2013-04-498139","article-title":"The impact of response on bone-directed therapy in patients with multiple myeloma","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-020-0297-2","article-title":"Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma","volume":"10","author":"Gavriatopoulou","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41408-023-00880-0","article-title":"Potential value of pre-planned imaging of bone disease in multiple myeloma","volume":"13","author":"Gundesen","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08293.x","article-title":"Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma","volume":"151","author":"Lund","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Papanota, A.-M., Karousi, P., Kontos, C.K., Ntanasis-Stathopoulos, I., Scorilas, A., and Terpos, E. (2021). Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052375"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Papanota, A.-M., Tsiakanikas, P., Kontos, C.K., Malandrakis, P., Liacos, C.-I., Ntanasis-Stathopoulos, I., Kanellias, N., Gavriatopoulou, M., Kastritis, E., and Avgeris, M. (2021). A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13153877"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101703","DOI":"10.1016\/j.bonr.2023.101703","article-title":"Trabecular bone deterioration in a postmenopausal female suffering multiple spontaneous vertebral fractures due to a delayed denosumab injection\u2014A post-treatment re-initiation bone biopsy-based case study","volume":"19","author":"Drejer","year":"2023","journal-title":"Bone Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/M20-0882","article-title":"Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis: A Population-Based Cohort Study","volume":"173","author":"Lyu","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: A Randomized Trial","volume":"35","author":"Langdahl","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/jbmr.4259","article-title":"Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension","volume":"36","author":"Ramchand","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial","volume":"100","author":"Oriol","year":"2015","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: A consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Malhotra, K., Butler, J.S., Yu, H.M., Selvadurai, S., D\u2019sa, S., Rabin, N., Kyriakou, C., Yong, K., and Molloy, S. (2016). Spinal disease in myeloma: Cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2495-7"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13013-016-0107-6","article-title":"Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma","volume":"11","author":"Audat","year":"2016","journal-title":"Scoliosis Spinal Disord."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1470-2045(11)70008-0","article-title":"Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomised controlled trial","volume":"12","author":"Berenson","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5152\/dir.2016.15201","article-title":"Effectiveness of percutaneous vertebroplasty in patients with multiple myeloma having vertebral pain","volume":"22","author":"Nas","year":"2016","journal-title":"Diagn. Interv. Radiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(10)60954-3","article-title":"Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): An open-label randomised trial","volume":"376","author":"Klazen","year":"2010","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s00586-008-0701-2","article-title":"Balloon kyphoplasty in the treatment of metastatic disease of the spine: A 2-year prospective evaluation","volume":"17","author":"Pflugmacher","year":"2008","journal-title":"Eur. Spine J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00586-020-06392-w","article-title":"Percutaneous vertebroplasty as treatment of malignant vertebral lesions: A systematic review and GRADE evaluation resulting in a Danish national clinical guideline","volume":"29","author":"Rousing","year":"2020","journal-title":"Eur. Spine J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e045854","DOI":"10.1136\/bmjopen-2020-045854","article-title":"Vertebroplasty in patients with multiple myeloma with vertebral compression fractures: Protocol for a single-blind randomised controlled trial","volume":"11","author":"Wickstroem","year":"2021","journal-title":"BMJ Open"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jbmr.4815","article-title":"A Critical Role of the Bone Marrow Envelope in Human Bone Remodeling","volume":"38","author":"Andersen","year":"2023","journal-title":"J. Bone Miner. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1359\/jbmr.2001.16.9.1575","article-title":"Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers","volume":"16","author":"Hauge","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ajpath.2013.11.022","article-title":"Osteoblast recruitment routes in human cancellous bone remodeling","volume":"184","author":"Kristensen","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2003.04374.x","article-title":"Upregulation of osteoblast apoptosis by malignant plasma cells: A role in myeloma bone disease","volume":"122","author":"Silvestris","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1096\/fj.05-4329fje","article-title":"A role of TRAIL in killing osteoblasts by myeloma cells","volume":"20","author":"Tinhofer","year":"2006","journal-title":"FASEB J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood.V74.4.1266.1266","article-title":"Production of cytokines by bone marrow cells obtained from patients with multiple myeloma","volume":"74","author":"Lichtenstein","year":"1989","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann. N. Y Acad. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjh.12270","article-title":"Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease","volume":"161","author":"Kristensen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","article-title":"EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation","volume":"15","author":"Adamik","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Maiso, P., Mogoll\u00f3n, P., Ocio, E.M., and Garayoa, M. (2021). Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression. Cancers, 13.","DOI":"10.3390\/cancers13112542"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2002.03417.x","article-title":"RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma","volume":"117","author":"Roux","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1038\/s41467-022-31356-7","article-title":"Osteocyte CIITA aggravates osteolytic bone lesions in myeloma","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","article-title":"Role of osteocytes in multiple myeloma bone disease","volume":"8","author":"Bellido","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood.V122.21.3140.3140","article-title":"Direct Cell-To-Cell Interactions Between Osteocytes and Multiple Myeloma (MM) Cells Upregulate Sost and Downregulate OPG Expression In Osteocytes: Evidence For Osteocytic Contributions To MM-Induced Bone Disease","volume":"122","author":"Calle","year":"2013","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"584683","DOI":"10.3389\/fonc.2020.584683","article-title":"Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes","volume":"10","author":"Fairfield","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/carcin\/bgx045","article-title":"Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells\u2019 phenotype and translation initiation","volume":"38","author":"Dabbah","year":"2017","journal-title":"Carcinogenesis"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trsl.2019.01.003","article-title":"BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner","volume":"207","author":"Ibraheem","year":"2019","journal-title":"Transl. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/carcin\/bgz169","article-title":"Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles","volume":"41","author":"Dabbah","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., and Lagneaux, L. (2013). Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059756"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.leu.2404466","article-title":"Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma","volume":"21","author":"Arnulf","year":"2007","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.3324\/haematol.2019.235135","article-title":"Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: Transcriptional modulation of the microenvironment","volume":"105","author":"Alameda","year":"2020","journal-title":"Haematologica"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bone.2016.08.006","article-title":"Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease","volume":"93","author":"Dotterweich","year":"2016","journal-title":"Bone"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.18632\/oncotarget.2058","article-title":"Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease","volume":"5","author":"Rivas","year":"2014","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-17-2627","article-title":"The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma","volume":"24","author":"Schinke","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41598-018-38314-8","article-title":"Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism","volume":"9","author":"Fernando","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lemaitre, L., Ferreira, L.D.S., Joubert, M.-V., Avet-Loiseau, H., Martinet, L., Corre, J., and Couderc, B. (2020). Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113854"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"Kellermayer","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/leu.2009.65","article-title":"Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors","volume":"23","author":"Garayoa","year":"2009","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41467-020-20715-x","article-title":"Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ejh.12125","article-title":"Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration","volume":"91","author":"Kristensen","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_124","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","article-title":"Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function","volume":"333","author":"Zavrski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.25392","article-title":"Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates","volume":"94","author":"Terpos","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Katodritou, E., Kyrtsonis, M.-C., Douka, V., Spanoudakis, E., Papatheodorou, A., Eleutherakis-Papaiakovou, E., Kanellias, N., and Gavriatopoulou, M. (2021). Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed\/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers, 13.","DOI":"10.3390\/cancers13061257"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpain.2006.09.014","article-title":"Quantitative sensory findings in patients with bortezomib-induced pain","volume":"8","author":"Cata","year":"2007","journal-title":"J. Pain"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Yin, J., Wei, J., and Shang, Z. (2014). Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087671"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2021.02.048","article-title":"Ixazomib inhibits myeloma cell proliferation by targeting UBE2K","volume":"549","author":"Wang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Tibullo, D., Longo, A., Vicario, N., Romano, A., Barbato, A., Di Rosa, M., Barbagallo, I., Anfuso, C.D., Lupo, G., and Gulino, R. (2020). Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells. Cancers, 12.","DOI":"10.3390\/cancers12020323"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","article-title":"Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease","volume":"20","author":"Quwaider","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.4807","article-title":"Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study","volume":"38","author":"Gundesen","year":"2023","journal-title":"J. Bone Miner. Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Kastritis, E., Hatjiharissi, E., Katodritou, E., Eleutherakis-Papaiakovou, E., Verrou, E., Gavriatopoulou, M., Leonidakis, A., and Manousou, K. (2022). Daratumumab Improves Bone Turnover in Relapsed\/Refractory Multiple Myeloma; Phase 2 Study \u201cREBUILD\u201d. Cancers, 14.","DOI":"10.3390\/cancers14112768"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Vasiliadis, E.S., Evangelopoulos, D.-S., Kaspiris, A., Benetos, I.S., Vlachos, C., and Pneumaticos, S.G. (2022). The Role of Sclerostin in Bone Diseases. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030806"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"999939","DOI":"10.3389\/fonc.2022.999939","article-title":"The role of the bone microenvironment in regulating myeloma residual disease and treatment","volume":"12","author":"Dadzie","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5585\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:30:23Z","timestamp":1760131823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":144,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15235585"],"URL":"https:\/\/doi.org\/10.3390\/cancers15235585","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]}}}